These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 15515791

  • 1. An unusual case of Behçet's syndrome: triggered by typhoid vaccination?
    Molloy ES, Powell FC, Doran MF, Ryan JG, Mulligan NJ, McCarthy CJ, Keogan MT, McCarthy GM.
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S71-4. PubMed ID: 15515791
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum.
    Daniels NH, Callen JP.
    Arch Dermatol; 2004 Dec; 140(12):1427-9. PubMed ID: 15611417
    [No Abstract] [Full Text] [Related]

  • 3. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA, Jamnitski A, Baarsma GS, van Daele PL, van Hagen PM.
    Ned Tijdschr Geneeskd; 2006 Apr 01; 150(13):705-9. PubMed ID: 16623340
    [Abstract] [Full Text] [Related]

  • 4. Behçet's syndrome: from aetiology to treatment.
    Powell RJ.
    Adv Exp Med Biol; 2003 Apr 01; 528():481-6. PubMed ID: 12918749
    [No Abstract] [Full Text] [Related]

  • 5. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis.
    Goldenberg G, Jorizzo JL.
    J Dermatolog Treat; 2005 Apr 01; 16(5-6):347-9. PubMed ID: 16428159
    [Abstract] [Full Text] [Related]

  • 6. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).
    Pastor N, Betlloch I, Pascual JC, Blanes M, Bañuls J, Silvestre JF.
    Clin Exp Dermatol; 2006 Jan 01; 31(1):152-3. PubMed ID: 16309525
    [No Abstract] [Full Text] [Related]

  • 7. A case of mucocutaneous Behçet's disease responding to etanercept.
    Sommer A, Altmeyer P, Kreuter A.
    J Am Acad Dermatol; 2005 Apr 01; 52(4):717-9. PubMed ID: 15793540
    [No Abstract] [Full Text] [Related]

  • 8. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE, Monaghan TM, Bamford JM.
    Clin Neurol Neurosurg; 2007 Apr 01; 109(3):279-81. PubMed ID: 17174468
    [Abstract] [Full Text] [Related]

  • 9. Pyoderma gangrenosum associated with Wegener's granulomatosis: partial response to mycophenolate mofetil.
    Le Hello C, Bonte I, Mora JJ, Verneuil L, Noël LH, Guillevin L.
    Rheumatology (Oxford); 2002 Feb 01; 41(2):236-7. PubMed ID: 11886982
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of thalidomide resistant pyoderma gangrenosum with etenercept.
    Guedes R, Moreira A, Menezes N, Baptista A, Varela P.
    Acta Dermatovenerol Croat; 2012 Feb 01; 20(3):175-80. PubMed ID: 23069303
    [Abstract] [Full Text] [Related]

  • 11. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.
    Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L.
    J Dtsch Dermatol Ges; 2013 May 01; 11(5):447-9. PubMed ID: 23343137
    [No Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil as therapy for pyoderma gangrenosum.
    Eaton PA, Callen JP.
    Arch Dermatol; 2009 Jul 01; 145(7):781-5. PubMed ID: 19620559
    [Abstract] [Full Text] [Related]

  • 13. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum.
    Nousari HC, Lynch W, Anhalt GJ, Petri M.
    Arch Dermatol; 1998 Dec 01; 134(12):1509-11. PubMed ID: 9875186
    [No Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum.
    Hohenleutner U, Mohr VD, Michel S, Landthaler M.
    Lancet; 1997 Dec 13; 350(9093):1748. PubMed ID: 9413469
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of etanercept in the treatment of a patient with Behçet's disease.
    Curigliano V, Giovinale M, Fonnesu C, Cerquaglia C, Verrecchia E, Turco S, Manganelli C, Manna R.
    Clin Rheumatol; 2008 Jul 13; 27(7):933-6. PubMed ID: 18330611
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration.
    Hernandez-Illas M, Tozman E, Fulcher SF, Jundt JW, Davis J, Pflugfelder SC.
    Eye Contact Lens; 2004 Jan 13; 30(1):2-5. PubMed ID: 14722460
    [Abstract] [Full Text] [Related]

  • 17. Severe bilateral optic neuritis post hepatitis A virus (HAV) and typhoid fever vaccination.
    O'Dowd S, Bafiq R, Ryan A, Cullinane A, Costello D.
    J Neurol Sci; 2015 Oct 15; 357(1-2):300-1. PubMed ID: 26145200
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of pyoderma gangrenosum with etanercept.
    McGowan JW, Johnson CA, Lynn A.
    J Drugs Dermatol; 2004 Oct 15; 3(4):441-4. PubMed ID: 15303791
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of resistant Behçet's disease with etanercept.
    Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M.
    Clin Exp Rheumatol; 2005 Oct 15; 23(5):729. PubMed ID: 16173263
    [No Abstract] [Full Text] [Related]

  • 20. The use of etanercept in the treatment of peristomal pyoderma gangrenosum.
    Kim FS, Pandya AG.
    Clin Exp Dermatol; 2012 Jun 15; 37(4):442-3. PubMed ID: 22582915
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.